Organ distribution of cisplatin after intraperitoneal administration of cisplatin-loaded microspheres
| Autor: | Hiroyuki Yoshino, Takehiko Suzuki, Takashi Tamura, Jun Imai, Yuji Horikiri, Akira Suzuki, Masahiko Tanimoto, Osamu Ike, Akihiro Matsumoto |
|---|---|
| Rok vydání: | 2002 |
| Předmět: |
inorganic chemicals
Male Pathology medicine.medical_specialty Ratón Urinary system Pharmaceutical Science Pharmacology Kidney Peritoneal cavity Mice Pharmacokinetics Medicine Animals Tissue Distribution neoplasms Lung Cisplatin business.industry Kidney metabolism General Medicine Xenograft Model Antitumor Assays female genital diseases and pregnancy complications Microspheres medicine.anatomical_structure Liver Area Under Curve Drug carrier business Injections Intraperitoneal Biotechnology medicine.drug |
| Zdroj: | European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V. 54(1) |
| ISSN: | 0939-6411 |
| Popis: | The aim of this study was to clarify the organ distribution of cisplatin (CDDP) after intraperitoneal (i.p.) administration of cisplatin-loaded microspheres (CDDP-MS). The distribution of CDDP to normal organs lying in the peritoneal cavity after i.p. administration of CDDP-MS was assessed by comparing with subcutaneous administration to non-cancerous mice. The organ distribution of CDDP after i.p. administration of CDDP-MS shows that CDDP released from microspheres was distributed to the organs lying in the peritoneal cavity and in the retroperitoneum. These are mainly from the systemic circulation, but are not directly from the organ surface. The distribution of CDDP to tumors was evaluated in sarcoma180 tumor-bearing mice by comparing with a bolus injection. The CDDP-MS delivered CDDP to tumors more effectively than did bolus injection. The distribution of CDDP-MS in the peritoneal cavity was in accord with the tumor distribution. This concordance and sustained exposure of CDDP to the tumors might play a critical role in enhancing the CDDP accumulation in tumors. It is concluded that CDDP-MS have a distinct regional pharmacokinetic advantage for peritoneal carcinomatosis, and that i.p. administration of CDDP-MS is an effective treatment for peritoneal carcinomatosis. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect